January 20, 2021 – Integra LifeSciences Holdings Corporation (Princeton, NJ) announced it completed the previously-disclosed acquisition of ACell, Inc.
ACell is an innovative regenerative medicine company with a product portfolio based on a proprietary porcine urinary bladder matrix platform technology, MatriStem UBM.
Integra announced on December 16, 2020, that it had entered into a definitive agreement to acquire ACell for an upfront cash payment of $300 million at closing, subject to customary purchase price adjustments, and cash payments of up to an additional $100 million upon the achievement of certain revenue growth milestones.
“Acquiring ACell and its proprietary MatriStem UBM technologies will enable Integra to provide more comprehensive complex wound management solutions to address our customers’ most pressing clinical challenges,” said Peter Arduini, president and CEO, Integra LifeSciences. “Together with ACell colleagues, we look forward to continuing to advance wound care innovations for our customers and patients.”
Final terms of the acquisition were not disclosed.